Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Luca Grumolato"'
Autor:
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2257-2274 (2023)
Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinas
Externí odkaz:
https://doaj.org/article/272f451e35f5414da2913aa27cf75f12
Autor:
María Victoria Castro, Gastón Alexis Barbero, María Belén Villanueva, Luca Grumolato, Jérémie Nsengimana, Julia Newton-Bishop, Edith Illescas, María Josefina Quezada, Pablo Lopez-Bergami
Publikováno v:
Journal of Biomedical Science, Vol 28, Iss 1, Pp 1-15 (2021)
Abstract Background Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a Wnt5a receptor aberrantly expressed in cancer that was shown to either suppress or promote carcinogenesis in different tumor types. Our goal was to study the role of ROR2
Externí odkaz:
https://doaj.org/article/4aa18ad8bb6d4dfa887f300feb49a3f7
Autor:
Anita Rogic, Ila Pant, Luca Grumolato, Ruben Fernandez-Rodriguez, Andrew Edwards, Suvendu Das, Aaron Sun, Shen Yao, Rui Qiao, Shabnam Jaffer, Ravi Sachidanandam, Guray Akturk, Rosa Karlic, Mihaela Skobe, Stuart A. Aaronson
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with a poor prognosis. Here the authors report the characterization of a human IBC cell line recapitulating the clinical and histopathological features of the human disease, and
Externí odkaz:
https://doaj.org/article/178a7e049b6748368cce8de609f3ab95
Publikováno v:
Cells, Vol 9, Iss 12, p 2601 (2020)
The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of toleran
Externí odkaz:
https://doaj.org/article/d3074e727c1549298ec38ff7692218a3
Publikováno v:
Cell Reports, Vol 5, Iss 2, Pp 302-313 (2013)
ErbB2 gene amplification occurs in 20%–25% of breast cancers, and its therapeutic targeting has markedly improved survival of patients with breast cancer in the adjuvant setting. However, resistance to these therapies can develop. Because epigeneti
Externí odkaz:
https://doaj.org/article/d7269b25d1f744fcb03197617faa83d6
Autor:
Luca Grumolato, Guizhong Liu, Tomomi Haremaki, Sathish Kumar Mungamuri, Phyllus Mong, Gal Akiri, Pablo Lopez-Bergami, Adriana Arita, Youssef Anouar, Marek Mlodzik, Ze'ev A Ronai, Joshua Brody, Daniel C Weinstein, Stuart A Aaronson
Publikováno v:
PLoS Genetics, Vol 9, Iss 8, p e1003603 (2013)
The role of Wnt signaling in embryonic development and stem cell maintenance is well established and aberrations leading to the constitutive up-regulation of this pathway are frequent in several types of human cancers. Upon ligand-mediated activation
Externí odkaz:
https://doaj.org/article/74e5edd7df0848589a031e25ce840979
Autor:
Luca Grumolato, Stuart A. Aaronson
Publikováno v:
Holland‐Frei Cancer Medicine. :1-10
Autor:
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche
Publikováno v:
Molecular Oncology.
Autor:
Pablo Lopez-Bergami, María Belén Villanueva, María Victoria Castro, Jérémie Nsengimana, María Josefina Quezada, Edith Illescas, Luca Grumolato, Gastón Barbero, Julia Newton-Bishop
Publikováno v:
Journal of Biomedical Science, Vol 28, Iss 1, Pp 1-15 (2021)
Journal of Biomedical Science
Journal of Biomedical Science
Background Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a Wnt5a receptor aberrantly expressed in cancer that was shown to either suppress or promote carcinogenesis in different tumor types. Our goal was to study the role of ROR2 in melan
Publikováno v:
Cancers. 15:504
Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally